Also found in: Dictionary, Thesaurus, Encyclopedia.


(sis'tēn-il), Do not confuse this word with cystinyl.
Aminoacyl radical of cysteine.
References in periodicals archive ?
We recommend that larger scale multicenter trials would better help to evaluate the role of cysteinyl leukotrienes antagonists in treating acute exacerbations of asthma.
27-29) One LOX enzyme in particular, 5-LOX, has been implicated in the production of the highly inflammatory cysteinyl leukotrienes and leukotriene (LT[B.
In inflammatory pathologies, such as bronchial asthma (12, 13) and allergic rhinitis (13, 14), in which LTs are known to play an essential role, different selective antagonists of cysteinyl LTs are shown to have a beneficial effect.
Albumin oxidation to diverse radicals by the peroxidase activity of Cu, Zn-superoxide dismutase in the presence of bicarbonate or nitrite: diffusible radicals produce cysteinyl and solvent-exposed and -unexposed tyrosyl radicals.
31] Various chemokines and a lipid mediator, cysteinyl leukotrienes ([CysLTs], the 5-lipoxygenase metabolites of arachidonic acid) are potent inflammatory mediators that are associated with I-R-induced tissue injury.
In children higher levels of cysteinyl leukotrienes have been found in those with SDB (32,33).
Segun Elmore (2007) la apoptosis se puede definir como: "un proceso coordinado, dependiente de energia, que involucra la activacion de un grupo de cistein proteasas denominadas 'caspasas' (en ingles: cysteinyl aspartate-specific proteases) y una compleja cascada de eventos que unen el estimulo inicial con la desaparicion definitiva de la celula".
They have a rapid onset of action (within 1-3 hours), (48) are administered orally, treat asthma via a different pathway to other currently available medications (specific cysteinyl leukotriene receptor antagonists), and have been shown to be effective for aspirin-sensitive asthma.
The immediate response is the early in which mast cells and basophils undergo degranulation to release histamine, and cysteinyl leukotrienes.
A major achievement of our program has been the development of the cysteinyl leukotriene-1 (CystLT1) receptor antagonist Singulair[R] (Figure 1).
Leukotriene receptor antagonists block the bronchoconstrictor and proinflammatory activity of cysteinyl leukotrienes (metabolites of arachodonic acid produced by mast cells, basophils and eosinophils) within the asthmatic airway.
It limits 5-1ipoxygenase pathway activation limiting the production of LTA4, LTC4, and the derivatives of cysteinyl LT, LTD4, and LTE4, which are potent vasoconstrictors (Balzano, Fuschillo, & Gaudiosi, 2002).